Condition: Cervical Cancers · Vaginal Cancers · Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
The aim of this clinical trial is to assess the oncologic safety of minimally invasive pelvic exenteration in patients with recurrence or persistence of cervical or vaginal cancer with pelvic location, suitable for pelvic exenteration according to the ESGO guidelines (European Society of Gynecological Oncology). The primary aim is to assess the 3-year disease-free survival (DFS). The secondary aim is to assess the 3-year overall survival (OS), the intraoperative and post-operative complication rate, and the patient's quality of life.
This description comes directly from the study's public registry record.
Nicolò Bizzarri · 0630156249 · nicolo.bizzarri@policlinicogemelli.it
Always discuss trial participation with your own doctor first.
| Policlinico Agostino Gemelli IRCCS | Rome, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06867445